217 related articles for article (PubMed ID: 36375042)
1. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G; Álvarez-Larrán A; Harrison C; Martínez-Ávila JC; Hernández-Boluda JC; Ferrer-Marín F; Radia DH; Mora E; Francis S; González-Martínez T; Goddard K; Pérez-Encinas M; Narayanan S; Raya JM; Singh V; Gutiérrez X; Toth P; Amat-Martínez P; Mcilwaine L; Alobaidi M; Mayani K; McGregor A; Stuckey R; Psaila B; Segura A; Alvares C; Davidson K; Osorio S; Cutting R; Sweeney CP; Rufián L; Moreno L; Cuenca I; Smith J; Morales ML; Gil-Manso R; Koutsavlis I; Wang L; Mead AJ; Rozman M; Martínez-López J; Ayala R; Cross NCP
Blood Adv; 2023 May; 7(9):1672-1681. PubMed ID: 36375042
[TBL] [Abstract][Full Text] [Related]
2. What's different about atypical CML and chronic neutrophilic leukemia?
Dao KH; Tyner JW
Hematology Am Soc Hematol Educ Program; 2015; 2015():264-71. PubMed ID: 26637732
[TBL] [Abstract][Full Text] [Related]
3. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Szuber N; Orazi A; Tefferi A
Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
[TBL] [Abstract][Full Text] [Related]
4. Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Tyner JW; Gotlib J
Curr Hematol Malig Rep; 2017 Oct; 12(5):432-441. PubMed ID: 28983816
[TBL] [Abstract][Full Text] [Related]
5. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
6. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
Kim SY; Song IC; Kim J; Kwon GC
Ann Diagn Pathol; 2024 Apr; 71():152317. PubMed ID: 38642470
[TBL] [Abstract][Full Text] [Related]
7. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
8. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.
Gotlib J; Maxson JE; George TI; Tyner JW
Blood; 2013 Sep; 122(10):1707-11. PubMed ID: 23896413
[TBL] [Abstract][Full Text] [Related]
9. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A
Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
Maxson JE; Gotlib J; Pollyea DA; Fleischman AG; Agarwal A; Eide CA; Bottomly D; Wilmot B; McWeeney SK; Tognon CE; Pond JB; Collins RH; Goueli B; Oh ST; Deininger MW; Chang BH; Loriaux MM; Druker BJ; Tyner JW
N Engl J Med; 2013 May; 368(19):1781-90. PubMed ID: 23656643
[TBL] [Abstract][Full Text] [Related]
11. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
12. Genomics of chronic neutrophilic leukemia.
Maxson JE; Tyner JW
Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
[TBL] [Abstract][Full Text] [Related]
13. Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice.
Tefferi A; Elliott M; Pardanani A
Curr Opin Hematol; 2015 Mar; 22(2):171-6. PubMed ID: 25575036
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
[TBL] [Abstract][Full Text] [Related]
15. CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.
Guastafierro V; Ubezio M; Manes N; Milanesi C; Della Porta M; Bonometti A
Leuk Lymphoma; 2023 Sep; 64(9):1566-1573. PubMed ID: 37395413
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.
Itonaga H; Ota S; Ikeda T; Taji H; Amano I; Hasegawa Y; Ichinohe T; Fukuda T; Atsuta Y; Tanizawa A; Kondo T; Miyazaki Y
Leuk Res; 2018 Dec; 75():50-57. PubMed ID: 30458320
[TBL] [Abstract][Full Text] [Related]
17. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia.
Meggendorfer M; Haferlach T; Alpermann T; Jeromin S; Haferlach C; Kern W; Schnittger S
Haematologica; 2014 Dec; 99(12):e244-6. PubMed ID: 25239264
[No Abstract] [Full Text] [Related]
18. Atypical Chronic Myeloid Leukemia: Where Are We Now?
Crisà E; Nicolosi M; Ferri V; Favini C; Gaidano G; Patriarca A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962122
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia-aCML).
Martino G; Quintini M; Martelli MP; Ascani S; Lazzi S; Mecucci C
Am J Hematol; 2023 Jul; 98(7):1163-1164. PubMed ID: 36594191
[TBL] [Abstract][Full Text] [Related]
20. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
